Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical Industries Limited (DE:TEV)
NYSE:TEV
Total Valuation
Teva Pharmaceutical has a market cap or net worth of €33.90B. The enterprise value is €53.46B.
Market Cap€33.90B
Enterprise Value€53.46B
Share Statistics
Teva Pharmaceutical has 1,150,138,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,150,138,700
Owned by Insiders0.39%
Owned by Institutions0.08%
Financial Efficiency
Teva Pharmaceutical’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 7.41%.
Return on Equity (ROE)0.18
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)7.41%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee466.41K
Profits Per Employee38.32K
Employee Count37,000
Asset Turnover0.42
Inventory Turnover2.62
Valuation Ratios
The current PE Ratio of Teva Pharmaceutical is 27.0. Teva Pharmaceutical’s PEG ratio is -0.14.
PE Ratio27.0
PS Ratio2.08
PB Ratio4.53
Price to Fair Value4.53
Price to FCF31.24
Price to Operating Cash Flow19.65
PEG Ratio-0.14
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of 17.26B and earned 1.41B in profits. Earnings per share was 1.23.
Revenue17.26B
Gross Profit8.94B
Operating Income2.16B
Pretax Income1.24B
Net Income1.41B
EBITDA3.14B
Earnings Per Share (EPS)1.23
Cash Flow
In the last 12 months, operating cash flow was 1.65B and capital expenditures -501.00M, giving a free cash flow of 1.15B billion.
Operating Cash Flow1.65B
Free Cash Flow1.15B
Free Cash Flow per Share1.00
Dividends & Yields
Teva Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change75.46%
50-Day Moving Average26.35
200-Day Moving Average18.52
Relative Strength Index (RSI)61.65
Average Volume (3m)2.73K
Important Dates
Teva Pharmaceutical upcoming earnings date is May 13, 2026, Before Open (Confirmed).
Last Earnings DateJan 28, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Teva Pharmaceutical as a current ratio of 1.04, with Debt / Equity ratio of 219.75%
Current Ratio1.04
Quick Ratio0.80
Debt to Market Cap0.48
Net Debt to EBITDA4.40
Interest Coverage Ratio2.35
Taxes
In the past 12 months, Teva Pharmaceutical has paid -180.00M in taxes.
Income Tax-180.00M
Effective Tax Rate-0.15
Enterprise Valuation
Teva Pharmaceutical EV to EBITDA ratio is 15.82, with an EV/FCF ratio of 43.28.
EV to Sales2.88
EV to EBITDA15.82
EV to Free Cash Flow43.28
EV to Operating Cash Flow30.13
Balance Sheet
Teva Pharmaceutical has €3.56B in cash and marketable securities with €17.38B in debt, giving a net cash position of -€13.83B billion.
Cash & Marketable Securities€3.56B
Total Debt€17.38B
Net Cash-€13.83B
Net Cash Per Share-€12.02
Tangible Book Value Per Share-€10.33
Margins
Gross margin is 51.76%, with operating margin of 12.50%, and net profit margin of 8.17%.
Gross Margin51.76%
Operating Margin12.50%
Pretax Margin7.17%
Net Profit Margin8.17%
EBITDA Margin18.20%
EBIT Margin12.39%
Analyst Forecast
The average price target for Teva Pharmaceutical is €33.28, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€33.28
Price Target Upside14.37% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast―